TELA
TELA Bio, Inc.NASDAQHealthcare$0.60+5.47%ClosedMarket Cap: $26.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.16
P/S
0.35
EV/EBITDA
-1.03
DCF Value
$1.45
FCF Yield
-101.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
67.7%
Operating Margin
-42.0%
Net Margin
-48.4%
ROE
-441.5%
ROA
-47.7%
ROIC
-53.2%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $20.9M | 65.9% | $-6.6M | $-9.0M | $-0.17 | — |
| FY 2025 | $80.3M | 67.7% | $-33.8M | $-38.8M | $-0.83 | — |
| Q3 2025 | $20.7M | 67.5% | $-7.6M | $-8.6M | $-0.19 | — |
| Q2 2025 | $20.2M | 69.8% | $-9.1M | $-9.9M | $-0.22 | — |
| Q1 2025 | $18.5M | 67.6% | $-10.5M | $-11.3M | $-0.25 | — |
| Q4 2024 | $17.6M | 63.6% | $-8.4M | $-9.2M | $-0.23 | — |
| FY 2024 | $69.3M | 67.1% | $-34.1M | $-37.8M | $-1.33 | — |
| Q3 2024 | $19.0M | 67.8% | $-9.4M | $-10.4M | $-0.42 | — |
| Q2 2024 | $16.1M | 68.8% | $-11.6M | $-12.6M | $-0.51 | — |
| Q1 2024 | $16.6M | 68.3% | $-4.8M | $-5.7M | $-0.23 | — |
| Q4 2023 | $17.0M | 68.4% | $-12.3M | $-12.9M | $-0.53 | — |
| FY 2023 | $58.5M | 68.6% | $-44.1M | $-46.7M | $-2.04 | — |